Related Experiment Videos
Dislodgment and accelerated degradation of Ras
1Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.
Biochemistry
|March 7, 1998
Summary
S-trans,trans-farnesylthiosalicylic acid (FTS) dislodges oncogenic Ras proteins from cell membranes, leading to their degradation and reduced cellular levels. This specific action inhibits cancer cell growth, offering a targeted therapeutic approach.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ras oncoproteins are crucial for cancer cell transformation.
- Membrane anchorage of Ras is essential for its activity.
- Farnesylcysteine is a key component for Ras membrane binding.
Purpose of the Study:
- To investigate the mechanism of S-trans,trans-farnesylthiosalicylic acid (FTS) in inhibiting Ras-transformed cells.
- To determine if FTS specifically interferes with Ras functions.
- To elucidate FTS's effect on Ras membrane localization and degradation.
Main Methods:
- Treatment of H-Ras-transformed (EJ) cells and Rat-1 cells with FTS.
- Analysis of Ras protein levels and membrane localization.
- Measurement of Ras protein half-life.
- Dose-response studies of FTS effects.
Main Results:
- FTS dislodges Ras from cell membranes, facilitating its degradation and reducing total cellular Ras.
- Ras degradation was rapid, with a half-life of 10 hours in FTS-treated cells versus 27 hours in controls.
- FTS demonstrated dose-dependent effects and selectivity towards oncogenic Ras.
- FTS did not affect normal Ras isoforms or other membrane proteins.
Conclusions:
- FTS specifically targets Ras membrane docking, leading to enhanced protein degradation.
- This mechanism underlies FTS's ability to inhibit the growth of Ras-transformed cancer cells.
- FTS represents a potential therapeutic agent for cancers driven by oncogenic Ras.